Working… Menu

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome (CIS-ON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00287079
Recruitment Status : Completed
First Posted : February 6, 2006
Results First Posted : April 4, 2012
Last Update Posted : December 27, 2013
EMD Serono Canada Inc.
Information provided by (Responsible Party):
Merck KGaA, Darmstadt, Germany

Brief Summary:

The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that present with Clinically Isolated Syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI). The secondary objectives are to:

  • Assess the effectiveness of sc IFN beta - 1a (Rebif®) therapy in reducing the proportion of patients with CIS converting to CDMS
  • Assess the safety of sc IFN beta - 1a (Rebif®) in the patients with CIS

Condition or disease Intervention/treatment Phase
Clinically Isolated Syndrome Drug: Rebif® Other: No Treatment Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS)
Study Start Date : October 2005
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rebif® Drug: Rebif®
44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks

No Treatment Other: No Treatment
No treatment for 96 weeks

Primary Outcome Measures :
  1. Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates [ Time Frame: Up to Week 96 ]
    CDMS was defined by the occurrence of a second exacerbation or relapse over 96 weeks in participants who presented with Clinically Isolated Syndrome (CIS) accompanied by an abnormal Magnetic Resonance Imaging (MRI) scan. Time was calculated from the date of the stabilization of the baseline CIS episode to the qualifying relapse for the CDMS.

Secondary Outcome Measures :
  1. Percentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS) [ Time Frame: Up to Week 96 ]
    CDMS was defined as the occurrence of a second exacerbation over 96 weeks in participants who presented with CIS accompanied by an abnormal MRI scan.

  2. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) [ Time Frame: Up to Week 96 ]
    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Months to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must have experienced a first clinical episode suggestive of demyelinating disease
  • Subject must present with an abnormal MRI displaying at least 3 T2 weighted hyperintense lesions typical of multiple sclerosis (MS)
  • Subject must be greater than or equal to 18 years old
  • Subject must have had onset of the clinical attack within the last 120 days
  • Subject must give written informed consent
  • Female subjects must be neither pregnant nor breast feeding, and must not be of child-bearing potential as defined by either:
  • Being post-menopausal or surgically sterile
  • Using hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study

Subjects electing treatment:

  • Subject must be eligible for Interferon-beta 1-a therapy

Exclusion Criteria:

  • Subject has evidence of other neurological diseases that could explain his/her symptomatology
  • Subject is pregnant or in lactation
  • Subject suffers from an intercurrent autoimmune disease
  • Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the procedures required by this study
  • Subject has received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, campath), within 12 months of study day 1

Subjects electing treatment:

  • Subject has inadequate liver function, defined by total bilirubin, aspartate transaminase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal values
  • Subject has inadequate bone marrow reserve, defined as white blood cell count less than 0.5 times the lower limit of normal
  • Subject has a known allergy to IFN or any of the excipients of the drug product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00287079

Layout table for location information
Canada, Ontario
Canadian Medical Information Office
Windsor, Barrie, Hamilton, Mississauga, Ontario, Canada
Sponsors and Collaborators
Merck KGaA, Darmstadt, Germany
EMD Serono Canada Inc.
Layout table for investigator information
Study Director: Medical Director EMD Serono Canada Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Merck KGaA, Darmstadt, Germany Identifier: NCT00287079    
Other Study ID Numbers: IMP 26222
First Posted: February 6, 2006    Key Record Dates
Results First Posted: April 4, 2012
Last Update Posted: December 27, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes